[go: up one dir, main page]

AR072002A1 - Cannabinoides en combinacion con agentes quimioterapicos no cannabinoides - Google Patents

Cannabinoides en combinacion con agentes quimioterapicos no cannabinoides

Info

Publication number
AR072002A1
AR072002A1 ARP090101999A ARP090101999A AR072002A1 AR 072002 A1 AR072002 A1 AR 072002A1 AR P090101999 A ARP090101999 A AR P090101999A AR P090101999 A ARP090101999 A AR P090101999A AR 072002 A1 AR072002 A1 AR 072002A1
Authority
AR
Argentina
Prior art keywords
cannabinoids
cannabinoid
combination
use according
agent
Prior art date
Application number
ARP090101999A
Other languages
English (en)
Inventor
Pastor Manuel Guzman
Diez Guillermo Velasco
Original Assignee
Otsuka Pharma Co Ltd
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Gw Pharma Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR072002A1 publication Critical patent/AR072002A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente se refiere al uso de uno o m s cannabinoides, particularmente THC y/o CBD en combinacion con un agente quimioter pico no cannabinoide en la fabricacion de un medicamento para el uso en el tratamiento de c ncer. En particular, el c ncer tratado es un tumor cerebral, m s particularmente un glioma, aun m s particularmente un glioblastoma multiforme (GBM). El agente quimioter pico no cannabinoide puede ser un modulador selectivo de receptor de estrogenos o un agente alquilante. Reivindicacion 10: El uso de acuerdo con la reivindicacion 9, caracterizado porque el modulador selectivo de receptor de estrogenos es seleccionado del grupo que consiste de: afimoxifeno (4-hidroxitamoxifeno); arzoxifeno; bazedoifeno; clomifeno; lasofoxifeno; ormeloxifeno, raloxifeno; tamoxifeno; y toremifeno. Reivindicacion 13: El uso de acuerdo con la reivindicacion 12, caracterizado porque el agente alquilante es seleccionado del grupo que consiste de: sulfonatos de alquilo; busulfano; etileniminas y metilmelaminas; hexametimelamina; altretamina; tiotepa; mostazas nitrogenadas; ciclofosfamida; mecloretamina; mustina; uramustina; mostaza de uracilo; melfalano; clorambucilo; ifosfamida; nitrosureas; carmustina; cisplatino; estreptozocina; triazenos; decarbazina; imidazotetrazinas; y temozolomida. Reivindicacion 18: El uso de acuerdo con la reivindicacion 1, caracterizado porque el uno o m s cannabinoides est n presentes como extractos vegetales, como compuestos puros, o una combinacion de los dos.
ARP090101999A 2008-06-04 2009-06-03 Cannabinoides en combinacion con agentes quimioterapicos no cannabinoides AR072002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0810203.0A GB2460672B (en) 2008-06-04 2008-06-04 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents

Publications (1)

Publication Number Publication Date
AR072002A1 true AR072002A1 (es) 2010-07-28

Family

ID=39638156

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101999A AR072002A1 (es) 2008-06-04 2009-06-03 Cannabinoides en combinacion con agentes quimioterapicos no cannabinoides

Country Status (24)

Country Link
US (3) US20110086113A1 (es)
EP (2) EP3213748B1 (es)
JP (2) JP5674649B2 (es)
KR (1) KR20110053944A (es)
CN (1) CN102083426B (es)
AR (1) AR072002A1 (es)
AU (1) AU2009254935B2 (es)
BR (1) BRPI0911384A8 (es)
CA (1) CA2726257C (es)
CO (1) CO6341551A2 (es)
DK (1) DK2320881T3 (es)
ES (2) ES2887084T3 (es)
GB (2) GB2460672B (es)
IL (1) IL209739A0 (es)
MX (1) MX2010013036A (es)
MY (1) MY156264A (es)
NZ (1) NZ589373A (es)
PT (1) PT2320881T (es)
RU (1) RU2543034C2 (es)
SG (1) SG191643A1 (es)
TW (1) TWI469777B (es)
UA (1) UA104589C2 (es)
WO (1) WO2009147438A1 (es)
ZA (1) ZA201008558B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2554592B (en) * 2010-03-12 2018-07-11 Gw Pharma Ltd A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3250200A4 (en) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US20170189373A1 (en) * 2015-05-15 2017-07-06 Andrew Hospodor Terpene Control in Scaleable Cannabinoid Medicinal Formulations
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
IL258854B2 (en) * 2015-10-27 2025-06-01 Jay Pharma Inc Preparations containing cannabidiol and secondary pharmacological agents for cancer treatment
WO2017091764A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
AU2018325465A1 (en) * 2017-09-02 2020-05-28 Scientific Holdings, Llc Tetrahydrocannabinol modulators
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
WO2021028646A1 (en) * 2019-08-09 2021-02-18 Jay Pharma Inc. Administration regimes of cannabinoids in combination with chemotherapeutics against cancer
EP4017482A4 (en) * 2019-08-19 2023-12-20 Diverse Biotech, Inc. PLATINUM COMPLEX ANTINEOPLASTICS WITH A CANNABINOID LIGAND
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
MX2022004257A (es) 2019-10-11 2022-05-26 Pike Therapeutics Inc Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12097293B2 (en) 2019-10-14 2024-09-24 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
AU2022375771A1 (en) 2021-10-26 2024-05-23 Dove Innovation Pty Limited Methods of treating ovarian cancer with hemp extract
US11654172B2 (en) 2021-10-26 2023-05-23 Ecofibre Limited Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
KR20240122436A (ko) 2021-10-26 2024-08-12 에코파이버 유에스에이 인코포레이티드 대마 추출물을 생성하기 위한 시스템 및 방법과 조성물
IL320518A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Stabilized compositions containing cannabidiol
EP4608425A1 (en) 2022-10-26 2025-09-03 Ecofibre USA Inc. Methods of treating estrogen sensitive diseases with cannabis extract
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
RU2166948C1 (ru) * 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Способ лечения глиом с эпилептическим синдромом
CA2422320A1 (en) * 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
WO2003091189A1 (en) * 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
UA71391A (uk) * 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб променевої терапії при лікуванні гліом головного мозку
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
CA2603853C (en) * 2005-04-01 2013-11-19 Intezyne Technologies, Incorporated Polymeric micelles for drug delivery
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
JP2008540570A (ja) * 2005-05-13 2008-11-20 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 遅発性化学療法誘発悪心及び嘔吐のドロナビノール治療
KR100675281B1 (ko) * 2005-09-05 2007-01-29 삼성전자주식회사 디커플링 캐패시터를 갖는 반도체 소자 및 그 제조방법
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma

Also Published As

Publication number Publication date
EP2320881B1 (en) 2017-09-20
CN102083426A (zh) 2011-06-01
KR20110053944A (ko) 2011-05-24
PT2320881T (pt) 2017-12-22
DK2320881T3 (en) 2018-01-02
IL209739A0 (en) 2011-02-28
GB0810203D0 (en) 2008-07-09
TW201002316A (en) 2010-01-16
GB201101072D0 (en) 2011-03-09
JP2011522028A (ja) 2011-07-28
CN102083426B (zh) 2015-05-13
EP3213748B1 (en) 2021-08-18
US20110086113A1 (en) 2011-04-14
RU2543034C2 (ru) 2015-02-27
TWI469777B (zh) 2015-01-21
CO6341551A2 (es) 2011-11-21
CA2726257A1 (en) 2009-12-10
US20210069333A1 (en) 2021-03-11
UA104589C2 (ru) 2014-02-25
CA2726257C (en) 2016-09-13
JP5674649B2 (ja) 2015-02-25
ES2653200T3 (es) 2018-02-06
ES2887084T3 (es) 2021-12-21
EP2320881A1 (en) 2011-05-18
GB2460672B (en) 2012-01-04
SG191643A1 (en) 2013-07-31
NZ589373A (en) 2013-05-31
MY156264A (en) 2016-01-29
ZA201008558B (en) 2014-11-26
RU2010154672A (ru) 2012-07-20
AU2009254935B2 (en) 2015-03-19
GB2475183A (en) 2011-05-11
MX2010013036A (es) 2011-02-18
GB2475183B (en) 2011-11-23
BRPI0911384A2 (pt) 2015-12-29
EP3213748A1 (en) 2017-09-06
WO2009147438A1 (en) 2009-12-10
JP2015057411A (ja) 2015-03-26
GB2460672A (en) 2009-12-09
US20190099492A1 (en) 2019-04-04
AU2009254935A1 (en) 2009-12-10
BRPI0911384A8 (pt) 2018-04-03

Similar Documents

Publication Publication Date Title
AR072002A1 (es) Cannabinoides en combinacion con agentes quimioterapicos no cannabinoides
AR064010A1 (es) Inhibidores de la actividad de la akt
ECSP10010589A (es) Farmaco contra el cancer de higado
BR112012023021A2 (pt) compostos de indazol e seus usos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
CL2008003158A1 (es) Compuestos derivados de diariltiohidantoina con actividad antagonista fuerte y con actividad agonista minima sobre el receptor de androgeno (ar); procedimiento de preparacion; composicion farmaceutica que los comprende; uso en el tratamiento de un desorden proliferativo tal como cancer de prostata.
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
BR112013002375A2 (pt) composto, composição farmacêutica, métodos de tratar um indivíduo para um distúrbio proliferativo de induzir a apoptose das células cancerígenas, e de inibir a atividade de cinase em um mamífero, e, processo de preparação de composto
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR067673A1 (es) Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
AR042042A1 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
AR051698A1 (es) Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa
CO6390117A2 (es) Regimen de dosificación para un agonista de los receptores de s1p
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
CR20120448A (es) Compuesto heterocíclico
MX2013010770A (es) Tratamiento de tumores solidos.
EA201792650A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
CL2008001213A1 (es) Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer.
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure